用于癌症免疫治疗的嵌合抗原受体工程化天然免疫细胞的前景。
The landscape of CAR-engineered innate immune cells for cancer immunotherapy.
作者信息
Tsahouridis Ourania, Xu Max, Song Feifei, Savoldo Barbara, Dotti Gianpietro
机构信息
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
出版信息
Nat Cancer. 2025 Jul 18. doi: 10.1038/s43018-025-01015-z.
Chimeric antigen receptor (CAR) T cells have improved the cure rate and quality of life of patients with lymphoid malignancies but have yet to demonstrate clinical benefits in solid tumors. Thus, several CAR-engineering strategies are currently being explored to overcome the functional limitations and the high cost of CAR T cells. Key among these are CAR-engineered innate immune cells, such as natural killer (NK) cells, NK T (NKT) cells, γδ T cells and macrophages. In this Review, we discuss the potential and limitations of efforts to develop and use innate immune CAR-engineered cells for cancer immunotherapy.
嵌合抗原受体（CAR）T细胞提高了淋巴系统恶性肿瘤患者的治愈率和生活质量，但尚未在实体瘤中显示出临床益处。因此，目前正在探索几种CAR工程策略，以克服CAR T细胞的功能限制和高昂成本。其中关键的是CAR工程化的先天免疫细胞，如自然杀伤（NK）细胞、自然杀伤T（NKT）细胞、γδT细胞和巨噬细胞。在本综述中，我们讨论了开发和使用先天免疫CAR工程化细胞进行癌症免疫治疗的潜力和局限性。
Zotero 插件